AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10983362
Drug: Maprotiline (10-25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maprotiline (10-25 mg/daily)
Trial: 9313603
Drug: Mibefradil 6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mibefradil 6.25 mg, 12.5 mg, 25 mg, 50 mg, 100 mg
Trial: 8383396
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment based on ambulatory monitoring
Trial: 8383396
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment based on conventional sphygmomanometry
Trial: 25714534
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine gel (Group Gel)
Trial: 17339157
Drug: 7.5 mL
RxNorm normalized name: 7.5 ML Spevigo 60 MG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mL autologous blood
Trial: 17339157
Drug: 15 mL
RxNorm normalized name: ethanol 0.15 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mL autologous blood
Trial: 2089087
Drug: Moclobemide (300-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (300-600 mg/d)
Trial: 2089087
Drug: Imipramine (100-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (100-200 mg/d)
Trial: 30117365
Drug: BCAA (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA (20 g/day)
Trial: 30117365
Drug: Omega-3 (2,700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 (2,700 mg/day)
Trial: 24113764
Drug: Treatment-as-usual control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual control condition
Trial: 9740261
Drug: Artemether 300
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Artemether 300 mg plus Pyrimethamine 100 mg
Trial: 9740261
Drug: Artemether 300
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Artemether 300 mg
Trial: 9740261
Drug: Pyrimethamine 100
RxNorm normalized name: pyrimethamine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrimethamine 100 mg
Trial: 23607501
Drug: TAFF (Separation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAFF (Separation Anxiety Family Therapy)
Trial: 23607501
Drug: CC (Coping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC (Coping Cat)
Trial: 23607501
Drug: Both TAFF
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both TAFF and CC
Trial: 21479682
Drug: Sivelestat administered
RxNorm normalized name: Sivelestat
DrugBank: Sivelestat (DB12863)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Sivelestat administered until postoperative day (POD) 2 (Group A)
Trial: 21479682
Drug: Sivelestat administered
RxNorm normalized name: Sivelestat
DrugBank: Sivelestat (DB12863)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Sivelestat administered until postoperative day (POD) 5 (Group B)
Trial: 21479682
Drug: Historical controls
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical controls without Sivelestat administration
Trial: 19783715
Drug: Phentermine 15
RxNorm normalized name: phentermine 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentermine 15 mg with Taranabant 0.5 mg
Trial: 19783715
Drug: Phentermine 15
RxNorm normalized name: phentermine 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentermine 15 mg with Taranabant 2 mg
Trial: 19783715
Drug: Phentermine 15
RxNorm normalized name: phentermine 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentermine 15 mg without Taranabant
Trial: 19783715
Drug: Phentermine 15
RxNorm normalized name: phentermine 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentermine 15 mg with Taranabant 1 mg
Trial: 16981054
Drug: Transport with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transport with platelet GP IIb/IIIa receptor inhibitor (tirofiban; 10 mg/kg IV bolus followed by 0.1 mg/kg/min infusion during transport)
Trial: 9038856
Drug: Regular human
RxNorm normalized name: insulin regular human recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular human insulin at 2.0 mU.kg‐1.min‐1
Trial: 9038856
Drug: Regular human
RxNorm normalized name: insulin regular human recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular human insulin at 4.0 mU.kg‐1.min‐1
Trial: 8587082
Drug: Nabumetone 1000-1500
RxNorm normalized name: nabumetone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabumetone 1000-1500 mg po daily
Trial: 8587082
Drug: Diclofenac SR
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac SR 100-150 mg po daily
Trial: 23596006
Drug: Intracoronary injection
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of bone marrow-derived mononuclear cells (BM-MNC) early (5 to 7 days after MI)
Trial: 23596006
Drug: Intracoronary injection
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of bone marrow-derived mononuclear cells (BM-MNC) late (3 to 4 weeks after MI)
Trial: 22833405
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no BM-MNC treatment)
Trial: 20143531
Drug: Bevacizumab (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (1.25 mg administered into the vitreous body)
Trial: 17117128
Drug: Non-goal-directed therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-goal-directed therapy
Trial: 11342894
Drug: Crushed tablets
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crushed tablets
Trial: 11342894
Drug: Chewed tablets
RxNorm normalized name: Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chewed tablets
Trial: 11342894
Drug: Whole tablets
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole tablets
Trial: 1833301
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg DHAS i.v. administration
Trial: 6623364
Drug: CPAP/IMV (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP/IMV (high tidal volumes 12 to 18 ml/kg)
Trial: 6623364
Drug: ZEEP/A-CM (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZEEP/A-CM (low tidal volumes 8 to 10 ml/kg)
Trial: 28174353
Drug: Montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 10 mg daily for 30 days
Trial: 22854880
Drug: Cocoa beverages
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa beverages (30-900 mg flavanol per day)
Trial: 18634706
Drug: 6-week herring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-week herring diet (150 g baked herring fillets/d, 5 d/week)
Trial: 18634706
Drug: Reference diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference diet (150 g baked lean pork and chicken fillets/d, 5 d/week)
Trial: 17961422
Drug: Pravastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (20 mg/d on top of standard therapy)
Trial: 9824387
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (1600 microg/day)
Trial: 9824387
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (1600 microg/day) plus oral prednisolone (5 mg/day)
Trial: 7650226
Drug: 80-mg immediate-release
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80-mg immediate-release (IR) tablet, phase A
Trial: 7650226
Drug: Two 80-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 80-mg IR tablets, phase B
Trial: 7650226
Drug: 160-mg controlled-release
RxNorm normalized name: Betadur CR 160 MG Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160-mg controlled-release capsule, phase C
Trial: 7650226
Drug: 10-mg IV
RxNorm normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-mg IV bolus, phase D
Trial: 2192716
Drug: Dispersible tablets
RxNorm normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dispersible tablets (2 X 150 mg)
Trial: 2192716
Drug: Film-coated tablets
RxNorm normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Film-coated tablets (2 X 150 mg)
Trial: 422304
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of propranolol and dihydrallazine
Trial: 28411506
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy followed by PEP (CBT+PEP)
Trial: 25256567
Drug: Standard hemodiafiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard hemodiafiltration (HDF) with bicarbonate (34 mmol/L) and acetate dialysate (3 mmol/L)
Trial: 21857144
Drug: Triple antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antiplatelet therapy (TAT; addition of cilostazol to dual antiplatelet therapy)
Trial: 29773949
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAT)
Trial: 17503066
Drug: Antibiotic ointment
RxNorm normalized name: CVS Antibiotic Ointment
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic ointment with hydrocortisone acetate (AB + HC)
Trial: 17503066
Drug: Antibiotic ointment
RxNorm normalized name: CVS Antibiotic Ointment
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic ointment (AB)
Trial: 15025615
Drug: Ketamine 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.4 mg kg(‐1)
Trial: 15025615
Drug: Lidocaine 2.5
RxNorm normalized name: LIDOCAINE 2.5% OINT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2.5 mg kg(‐1)
Trial: 9161392
Drug: DVT prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DVT prophylaxis using low-dose heparin sodium therapy (5000 U every 12 hours) and calf-length intermittent mechanical compression devices
Trial: 2905803
Drug: Buspirone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (5 or 10 mg)
Trial: 28838263
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 10-15 mg/week for minimum 12 weeks
Trial: 26520413
Drug: Prebiotic supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic supplementation with inulin (10 g/day)
Trial: 18823395
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg zoledronate i.v. every 3 months for 2 years (8 infusions)
Trial: 18823395
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (placebo) every 3 months for 2 years (8 infusions)
Trial: 15125825
Drug: Insulin in
RxNorm normalized name: insulin inhalation chamber
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin in addition to unchanged oral hypoglycemic medication (IC group)
Trial: 15125825
Drug: Insulin monotherapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin monotherapy (IM group)
Trial: 12563567
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil 2 mg o.d.
Trial: 12563567
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil 4 mg o.d.
Trial: 12563567
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil 8 mg o.d.
Trial: 28974305
Drug: Ultrasound-guided SGB
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided SGB (n = 20) with a 6-mL injection of 1% lidocaine
Trial: 28974305
Drug: Sham procedure
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sham procedure (n = 20) with a 6-mL injection of 0.9% saline
Trial: 27358638
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment intervention (Control)
Trial: 22214287
Drug: Invasive strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive strategy (stenting of the infarct-related coronary artery with abciximab as adjunct treatment)
Trial: 31982398
Drug: Exogenous progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Exogenous progesterone administered intraperitoneally
Trial: 31035017
Drug: ARD-3150 (inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARD-3150 (inhaled liposomal ciprofloxacin)
Trial: 14681846
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g butter + 40 g alcohol + 50 g carbohydrate
Trial: 14681846
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g butter alone
Trial: 14681846
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g butter + 120 g carbohydrate
Trial: 9833177
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil 8 mg o.i.d. (increased to 16 mg o.i.d. if necessary)
Trial: 3154330
Drug: Chlorthalidone 25
RxNorm normalized name: chlorthalidone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 25 mg daily
Trial: 3154330
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (Nifedipine + Chlorthalidone)
Trial: 25259674
Drug: Levomilnacipran ER
RxNorm normalized name: levomilnacipran Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levomilnacipran ER (40, 80, 120 mg/day)
Trial: 16505046
Drug: Diphenhydramine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine (1.0 mg/min over 50 minutes)
Trial: 9062618
Drug: Intravenous oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous oxycodone hydrochloride 0.05 mg/kg
Trial: 9062618
Drug: Intranasal oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal oxycodone hydrochloride 0.1 mg/kg
Trial: 8330469
Drug: Low-dose enteric-coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose enteric-coated aspirin (100 mg daily)
Trial: 3777411
Drug: 1% methohexital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% methohexital solution at 20 mg/kg body wt.
Trial: 3777411
Drug: 1% methohexital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% methohexital solution at 25 mg/kg body wt.
Trial: 3777411
Drug: 5% methohexital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% methohexital solution
Trial: 3777411
Drug: 1% methohexital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% methohexital solution at 15 mg/kg body wt.
Trial: 3777411
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg body wt. and 10 mg/kg body wt. dosages
Trial: 29266290
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) treatment combined with fractional CO2 laser therapy
Trial: 29266290
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) administration after laser irradiation
Trial: 28735763
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no PRP treatment)
Trial: 27130705
Drug: Eplerenone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone (25 mg every other day, increased to 25 mg once daily on Day 30, and to 50 mg once daily on Day 60)
Trial: 27130705
Drug: Finerenone (2.5→5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finerenone (2.5→5, 5→10, 7.5→15, 10→20, and 15→20 mg, uptitrated on Day 30)
Trial: 27130705
Drug: Finerenone (10→20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finerenone (10→20 mg)
Trial: 11775204
Drug: Intravenous mannitolum
RxNorm normalized name: Mannitolum
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous mannitolum 250 ml
Trial: 11775204
Drug: Intravenous albumin
RxNorm normalized name: albumin human, USP Injection [Albuminar]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous albumin 20 g
Trial: 8858219
Drug: IGF‐I (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGF‐I (8 micrograms.kg‐1.h‐1) for 5 days by continuous subcutaneous infusion
Trial: 6734705
Drug: Piretanide (12,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piretanide (12, 24, 48, 96 mg)
Trial: 6734705
Drug: Piretanide (48
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piretanide (48 mg and 96 mg)
Trial: 26869012
Drug: Quetiapine 150
RxNorm normalized name: quetiapine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine 150 mg XL for seven nights
Trial: 26869012
Drug: Quetiapine 150
RxNorm normalized name: quetiapine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine 150 mg XL
Trial: 25081182
Drug: Control arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arm of the Costa Rica Vaccine Trial (2004-2010)
Trial: 22891782
Drug: Intravascular laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravascular laser irradiation of blood (ILIB) therapy for 1 hour daily for 15 days over 3 weeks
Trial: 11789263
Drug: Intravascular laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravascular laser irradiation of blood (ILIB) therapy
Trial: 19104122
Drug: Topical negative
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical negative pressure (TNP) wound closure using a locally constructed device
Trial: 2287558
Drug: Aspirin 1000
RxNorm normalized name: aspirin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 1000 mg
Trial: 2324921
Drug: Acetaminophen 500
RxNorm normalized name: acetaminophen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 500 mg
Trial: 16154478
Drug: All active
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All active treatments (Aspirin and Acetaminophen)
Trial: 12573299
Drug: Methyltestosterone (MT)
RxNorm normalized name: Methyltestosterone
DrugBank: Methyltestosterone (DB06710)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methyltestosterone (MT) 40 mg/day for 3 days, then 240 mg/day for 3 days
Trial: 1683189
Drug: Levocabastine nasal
RxNorm normalized name: levocabastine Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocabastine nasal spray (0.5 mg/mL)
Trial: 1683189
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate nasal spray (20 mg/mL)
Trial: 6793058
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplements (1000 iu daily)
Trial: 25803626
Drug: Synbiotics (Lactobacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotics (Lactobacillus acidophilus 10, 1 × 10(9)CFU; Lactobacillus rhamnosus HS 111, 1 × 10(9) CFU; Lactobacillus casei 10, 1 × 10(9) CFU; Bifidobacterium bifidum, 1 × 10(9)CFU; fructooligosaccharides (FOS) 100 mg), administered twice daily for 14 days
Trial: 21076316
Drug: CVD risk
RxNorm normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVD risk reduction intervention (16 weeks) including 150 minutes of regular exercise per week, 200-300 kcal reduced daily diet, one-on-one psychobehavioral counseling, and telephone coaching
Trial: 19784816
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg/day for 6 months
Trial: 17258855
Drug: Sildenafil 25
RxNorm normalized name: sildenafil 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 25 mg OD
Trial: 17258855
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of alfuzosin and sildenafil